miR-217调控lncRNA MALAT1影响食管鳞癌细胞的生物学行为

doi:10.13418/j.issn.1001-165x.2018.04.011

中国临床解剖学杂志 ›› 2018, Vol. 36 ›› Issue (4): 408-413.doi: 10.13418/j.issn.1001-165x.2018.04.011

miR-217调控lncRNA MALAT1影响食管鳞癌细胞的生物学行为

徐健，　江跃全，　蔡华荣，　尹哲，　张奇

重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室，重庆 400030

收稿日期:2018-04-25 出版日期:2018-07-25 发布日期:2018-08-21
通讯作者: 江跃全，博士，主任医师，E-mail: 12700205@qq.com
作者简介:徐健(1986-)，住院医师，研究方向:普胸外科肺癌、食管癌的基础与临床研究，Tel：18580220756，E-mail：songlm693@ sina.com
基金资助:
重庆市卫生局资助项目（2013-2-122 ）

miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells by regulating lncRNA MALAT1

XU Jian, JIANG Yue-quan, CAI Hua-rong, YIN Zhe, ZHANG Qi

Chongqing University Cancer Hospital, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing 400300，China

Received:2018-04-25 Online:2018-07-25 Published:2018-08-21

摘要/Abstract

摘要：

目的　探讨miR-217通过调控lncRNA MALAT1抑制食管鳞状细胞癌细胞的增殖，迁移和侵袭行为及其机制。方法　qPCR检测miR-217在食管鳞状细胞癌组织和不同细胞株中的表达情况；双荧光素酶报告基因检测miR-217与MALAT1之间的相互作用；MTT增殖实验检测抑制miR-217后食管鳞状细胞癌细胞的增殖能力的变化情况；划痕愈合试验和Transwell侵袭实验检测抑制miR-217后食管鳞状细胞癌细胞的迁移和侵袭行为的变化情况；Western blotting实验检测miR-217对MALAT1下游相关蛋白表达情况的影响。结果　与正常食管组织相比，食管鳞状细胞癌组织中miR-217的表达水平相对上调，与其他细胞株相比，Ec109细胞中miR-217表达最高；双荧光素酶实验证实miR-217能与MALAT1的3’ UTR特异性结合，可以调控MALAT1的表达与活性；抑制miR-217的表达后可以抑制食管鳞状细胞癌细胞的增殖、迁移和侵袭能力；抑制miR-217后MALAT1下游MIA2，ROBO1表达明显下调。结论　miR-217可以调控MALAT1的表达影响食管鳞状细胞癌细胞的生物学行为。

关键词: , MALAT1, 　食管鳞状细胞癌, 　miR-217, 　MIA2

Abstract:

Objective　To investigate the inhibitory effect of miR-217 on proliferation, migration and invasion of esophageal squamous cell carcinoma cells by regulating lncRNA MALAT1.　Methods　qPCR was used to detect the expression of miR-217 in esophageal squamous cell carcinoma and different cell lines. Dual luciferase reporter assay detected the interaction between miR-217 and MALAT1. MTT assay was used to detect the proliferation of esophageal squamous cell carcinoma cells after miR-217 was inhibited. Scratch healing assay and Transwell invasion assay were used to detect the migration and invasion of esophageal squamous carcinoma cells after miR-217 was inhibited. The effect of miR-217 on the expression of MALAT1 downstream protein was detected by Western blotting.　Results　Compared with normal esophageal tissue, the expression of miR-217 in esophageal squamous cell carcinoma was relatively up-regulated, and the expression of miR-217 was the highest in Ec109 cells compared with other cell lines. Dual luciferase assay confirmed that miR-217 could specifically bind to 3'UTR of MALAT1 and regulate the expression and activity of MALAT1. Inhibition of miR-217 expression could inhibit esophageal squamous cell carcinoma cell proliferation, migration and invasion ability. Down-regulation of miR-217 after MALAT1 MIA2, ROBO1 expression was significantly down-regulated.　Conclusion　miR-217 can regulate the expression of MALAT1 and affect the biological behavior of esophageal squamous cell carcinoma cells.

Key words: MALAT1, 　Esophageal squamous cell carcinoma, 　miR-217, 　mIA2

徐健，　江跃全，　蔡华荣，　尹哲，　张奇. miR-217调控lncRNA MALAT1影响食管鳞癌细胞的生物学行为[J]. 中国临床解剖学杂志, 2018, 36(4): 408-413.

XU Jian, JIANG Yue-quan, CAI Hua-rong, YIN Zhe, ZHANG Qi. miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells by regulating lncRNA MALAT1[J]. Chinese Journal Of Clinical Anatomy, 2018, 36(4): 408-413.

参考文献

[1] Lin DC, Hao JJ, Nagata Y, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma[J]. Nat Genet, 2014, 46(5): 467-473.
[2] Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis[J]. Am J Gastroenterol, 2014, 109(6): 822-827.
[3] Zeng W, Li H, Chen Y, et al. Survivin activates NF?κB p65 via the IKKβ promoter in esophageal squamous cell carcinoma[J]. Mol Med Rep, 2016, 13(2): 1869-1880.
\[4] Giri S, Pathak R, Aryal MR, et al. Incidence trend of esophageal squamous cell carcinoma: an analysis of surveillance epidemiology, and end results (SEER) database[J]. Cancer Causes Control, 2015, 26(1): 159-161.
[5] Wu C, Wang Z, Song X, et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations[J]. Nat Genet, 2014, 46(9): 1001-1006.
[6] Chen FJ, Sun M, Li SQ, et al. Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis[J]. Mol Carcinog, 2013, 52(11): 908-915.
[7] Yu C, Xue J, Zhu W, et al. Warburg meets non-coding RNAs: the emerging role of ncRNA in regulating the glucose metabolism of cancer cells[J]. Tumor Biol, 2015, 36(1): 81-94.
[8] Liu Y, Zhao L, Li D, et al. Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development[J]. Protein Cell, 2013, 4(12): 932-941.
[9] Liu Y, Zhang M, Liang L, et al. Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer[J]. Int J Clin Exp Pathol, 2015, 8(9): 11480-11489.
[10] Inamura K. Major tumor suppressor and oncogenic non-coding RNAs: clinical relevance in lung cancer[J]. Cells, 2017, 6(2): 12-19.
[11] Tee AE, Liu B, Song R, et al. The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression[J]. Oncotarget, 2016, 7(8): 8663-8675.
[12] Dong Y, Liang G, Yuan B, et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway[J]. Tumor Biol, 2015, 36(3): 1477-1486.
[13] Ren S, Liu Y, Xu W, et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer[J]. J Urol, 2013, 190(6): 2278-2287.　　　　　[14] Han Y, Wu Z, Wu T, et al. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by downregulation of MMP2 and inactivation of ERK/MAPK signaling[J]. Cell Death Dis, 2016, 7(3): e2123.
[15] Ren D, Li H, Li R, et al. Novel insight into MALAT-1 in cancer: therapeutic targets and clinical applications[J]. Oncol Lett, 2016, 11(3): 1621-1630.
[16] Wu Y, Huang C, Meng X, et al. Long noncoding RNA MALAT1: insights into its biogenesis and implications in human disease[J]. Curr Pharm Des, 2015, 21(34): 5017-5028.
[17] Zhang B, Mao YS, Diermeier SD, et al. Identification and characterization of a class of MALAT1-like genomic loci[J]. Cell Rep, 2017, 19(8): 1723-1738.
[18] Ma XY, Wang JH, Wang JL, et al. Malat1 as an evolutionarily conserved lncRNA, plays a positive role in regulating proliferation and maintaining undifferentiated status of early-stage hematopoietic cells[J]. BMC Genomics, 2015, 16(1): 676-685.
[19] Leti F, Legendre C, Still CD, et al. Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells[J]. Trans Res, 2017, 190: 25-39. e21.
[20] Lu L, Luo F, Liu Y, et al. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial–mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract[J]. Toxicol Appl Pharmacol, 2015, 289(2): 276-285.
[21] Wang X, Li M, Wang Z, et al. Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells[J]. J Biol Chem, 2015, 290(7): 3925-3935.
[22] Xiao H, Tang K, Liu P, et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma[J]. Oncotarget, 2015, 6(35): 38005-38009.
[23] Fesler A, Ju J. microRNA-based novel therapeutic development in gastrointestinal cancer[M]//Therapeutic Targets for Inflammation and Cancer: Novel Therapies for Digestive Diseases. 2017: 365-386.

miR-217调控lncRNA MALAT1影响食管鳞癌细胞的生物学行为

miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells by regulating lncRNA MALAT1

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	江剑宏, 段仁鹏, 李晓锋. 国人胆道三维重建解剖变异应用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 1-4.
[2]	郭红志, 王瑜, 张加琪, 梁海彬, 马梓玮, 冯伟, 吴忧, 司子燚. 血管铸型结合CT三维模型评估先兆子痫胎盘血管结构[J]. 中国临床解剖学杂志, 2024, 42(1): 5-10.
[3]	李佳伟, 张静, 李灿然, 兰文杰, 籍庆余, 郭志勇, 张云凤, 刘启, 陈清威, 李筱贺. 蒙古族人群股骨近端解剖参数X线测量[J]. 中国临床解剖学杂志, 2024, 42(1): 11-16.
[4]	李琨, 张燕, 郭冉, 郝咪咪, 吴轩宇, 徐艺芳, 王超群, 马文童, 张灵淇, 杨宏宇, 李志军, 张少杰, 王星. 儿童及青少年枕颈角与后枕颈角数字化测量及其临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 17-20.
[5]	李文, 杨思艺, 黄蕾, 卿霁雯, 蒋松涛, 张磊. 基于MRI探讨Lisfranc韧带的形态学特点及临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 21-25.
[6]	李凡凡, 徐阳, 王晓旭. 紫草素调节Nrf2/HO-1信号通路对实验性大鼠肉芽肿性小叶性乳腺炎的治疗作用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 26-32.
[7]	王兴航, 丁佳媛, 李放, 包翠芬, 阎丽菁. 人参皂苷Rg1通过抑制NLRP3炎症小体途径减轻氧糖剥夺/复供后小胶质细胞炎症反应[J]. 中国临床解剖学杂志, 2024, 42(1): 33-41.
[8]	程莹莹, 武建军, 蔡海燕, 焦旭文, 马江波, 丁银秀. 体外炎性诱导星形胶质细胞激活及功能分析[J]. 中国临床解剖学杂志, 2024, 42(1): 42-46.
[9]	祁志, 杨力, 贾秋叶, 陈浩伦, 段兆达, 吴春云. 依达拉奉经MAPKs通路对脂多糖激活的小胶质细胞Sirt3表达调控[J]. 中国临床解剖学杂志, 2024, 42(1): 47-53.
[10]	张晶晶, 王洪新. 黄芩苷通过PDGF/P38 MAPK信号通路对肺动脉高压大鼠的保护作用[J]. 中国临床解剖学杂志, 2024, 42(1): 54-58.
[11]	乐钦, 陈荣丽, 熊婧熙, 王婷怡, 蔡志恒, 易秋实, 曾心怡. 白芨多糖对大鼠跨区皮瓣choke区的影响[J]. 中国临床解剖学杂志, 2024, 42(1): 59-64.
[12]	李笑予, 张磊, 付磊, 李东波, 汪国友. 三步接骨法治疗Sanders Ⅱ型跟骨骨折的有限元研究[J]. 中国临床解剖学杂志, 2024, 42(1): 65-70.
[13]	吴研飞, 马剑雄, 卢斌, 王颖, 柏豪豪, 靳洪震, 马信龙. CT后处理技术重建CT值与终板抗压强度的相关性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 71-76.
[14]	庄万强, 唐毅, 骆勇刚, 张辉. 关节镜联合胫骨高位截骨术对髌骨位置及髌股关节功能影响的早中期回顾性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 77-82.
[15]	罗鹰, 窦伟誉, 吴小杭, 陈璟昆, 彭昌贵, 潘剑英 . 微创海马钢板内固定治疗跟骨骨折并发症的影响因素[J]. 中国临床解剖学杂志, 2024, 42(1): 83-88.